Emory University Home Page LF Support Center Home Page Rollins School of Public Health Home Page LF Support Center Home Page Background of the LF Support Center Our Research Initiatives About Lymphatic Filariasis LFSC Publications Resources LF Links LFSC Staff Contact the LF Support Center What's New

Lymphatic Filariasis Elimination in Haiti


Haiti map: Lymphatic Filariasis Elimination in the Americas Report 2002

Introduction
LF in Haiti
Goals, Objectives and Strategies
The LF Elimination Program
Outcomes and Measures of Success
Partners and Program Support
 

6,000,000 people are at risk of LF infection in Haiti.

2,130,000 people are estimated to be  infected with LF in Haiti.

10% of the population in endemic areas is currently covered by MDA activities.


Introduction

Haiti is one of four countries in the Americas Region with ongoing lymphatic filariasis (LF) transmission.  It is located in the Caribbean Ocean and occupies the western one-third of the island of Hispaniola. The Dominican Republic, another LF-endemic country, occupies the eastern two-thirds of the island.

 Quick Facts1

Statistic

Haiti

Population 

8 million

Population below 14 years 

39.5%

Life expectancy

54.4 years

Literacy rate

48% (males)
42% (females)

GNI per capita (purchasing power parity) 

$1580

Population below poverty line 

80%

 

 

 

 

 

 

The current program aims to treat ~ 6 million people with mass drug administration (MDA), using either once-yearly albendazole and diethylcarbamazine (DEC) pills or DEC-fortified salt in the period 2003-2008.  Initial efforts will concentrate on those at highest risk, the red and dark blue zones on the map.  The cost of this program is approximately $1,000,000 per year, funding that will end in 2004.  Treatment of the entire at-risk population will require approximately $3 million per year for tablet-based programs or $1.5 million per year for DEC salt. 

top of page


LF in Haiti

 

Statistic

Haiti

Percentage of population at risk

75%

Percentage of population infected

30%

Percentage of population with lymphedema

Not Available

Percentage of population with hydrocele

Not Available

 

 

 

85% of Haiti’s population lives in areas at risk of LF transmission.  According to a 2001 antigen survey, 117 of 133 communes are endemic for LF.  In 2002, an estimated 2,130,000 people (30% of the total population) were thought to be infected2.  Surveys are currently being conducted to find the prevalence of lymphedema and hydrocele nationwide. 

The parasite responsible for LF in Haiti is Wuchereria bancrofti spread mainly by Culex mosquitoes. 

top of page


Goals

  • To eliminate LF from Haiti.  
  • To decrease suffering from and worsening of LF-related disability.

Objectives

  • Provide mass treatment so that all areas with a prevalence greater than 0.1% will be treated by 2008.

  • Facilitate behavior change among infected individuals.

  • Provide the de-worming benefits of albendazole to endemic communities, which will promote the healthy growth of children.

Strategies

  • Expand MDA campaigns.
  • Complete morbidity surveys.
  • Increase the number of community-based support groups.
  • Continue operational research to optimize patient care and monitoring and evaluation techniques.

top of page


The LF Elimination Program

Organization

In 2000, the Ministry of Public Health established a national coordinating center for the LF program, along with 4 technical subcommittees – mass treatment, clinical care, social mobilization, and diethylcarbamazine (DEC) fortified salt.  In 2003, the national program created a management team to direct activities throughout the country. 

Mass Drug Administration Activities

Mass drug administration (MDA) campaigns, using once-yearly albendazole and DEC, have been ongoing in Leogane since 2000.  The MOPH has begun campaigns in other areas, prioritizing those with greatest prevalence.  By 2002, 10% of the at-risk population was covered by MDA campaigns.  The program plans to implement MDAs in 16 areas, covering a million people in 2003. 

DEC-fortified salt use will be the strategy to interrupt transmission in three implementation units.  Honeywell International has donated 300 kg of DEC and WHO has donated 3000 kg of powdered DEC to add to local salt.  The program expects to treat 100,000 people with fortified salt in 2004.

Social Mobilization

Posters, flipcharts, radio spots, songs and lymphedema treatment materials have been developed in Haitian Creole.  These materials are used for education and advocacy purposes.  In 2003, 25 local leaders were educated about LF and how to interrupt transmission, 229 people were trained on how to transmit LF information to the public, and 1,628 local distributors were trained.

When drug coverage decreased in Leogane after the second round of MDA, the social mobilization team conducted focus groups to discover the cause.  Using results from these groups, they decided to increase awareness regarding adverse side effects and to increase the number of distribution posts.  Because of these efforts, coverage increased for the third round, completed in 2002.

Health Worker Training

A conference was held in 2002 for private physicians in Haiti.  It focused on the epidemiology of the disease and the objectives of the national elimination program.  In addition, a training manual was developed for physicians-in-training to inform them regarding LF and the lymphedema and urogenital disorders that can follow.  Also in 2002, Haiti hosted an international conference on urogenital ultrasound and surgery.  In total, 15 training sessions occurred, in which 2,300 health care workers were educated about different program components.  The program's next goal is to expand training for lab technicians in diagnosing LF infection.

Monitoring and Evaluation

Four sentinel sites were established in Leogane in 2000, surveying microfilarial (mf) and circulating antigen levels before treatment and after each round of MDA.  MF prevalence in sentinel sites has decreased from 9% positive in 2000 to 2% positive in 2002.  In 2002, eleven sites in other areas were established. 

A study of different strategies to assess coverage found little difference between community-based cluster surveys, surveys based on distribution points and school-based surveys.  This result will help the national program use cost-effective and accurate ways to monitor the program activities. 

Morbidity/Disability Activities

 In 2002, over 1200 patients were treated at the LF clinic in Leogane and over 500 were treated at the clinic in Milot.  In 2003, the Leogane clinic treated 176 new patients and the Milot clinic treated 72 new patients and enrolled 514 people in support groups.  In addition, in total, the Leogane clinic has performed 171 hydrocele surgeries and facilitated 864 support group meetings.

The program aims to expand LF clinics so that the six areas with greatest LF burden will each have a functioning LF clinic, complete with urologic surgery facilities, by 2004.

Economic Research

A cost analysis of the Haiti MDA program is ongoing in conjunction with the Emory LF Support Center.  The Haiti MOPH is using information from the cost analysis on the first two years of MDA in Leogane to create a budget for the national program.  A cost-effectiveness analysis of prevention and treatment programs will be completed in 2004. 

Operational Research

The CDC, in conjunction with the Haitian MOPH and the University of Notre Dame, has been working in Leogane for twenty years, conducting research on strategies to combat LF.  Results from the operational research have been used to refine the national program strategy, to improve implementation of country programs globally and to prove the validity of different strategies and activities in controlling LF. 

top of page


Outcomes

Mass Drug Administration Outcomes 

Year

Area

Population

% Coverage

Remarks*

2000

Leogane

   150,000

71%

Surveyed coverage

2001

Leogane

   150,000

70.5%
61.9%

Reported coverage
Surveyed coverage

2002

9 areas

   510,795

86%
77%

Reported coverage
Surveyed coverage

2003

16 areas 

1,000,000

 

 

2004

                         3 areas

2,000,000
   100,000

 

 
DEC-fortified salt

*Reported coverage (%) is defined as the total number of individuals seen to ingest the appropriate dose of drug x 100 / total population residing in areas where the MDA was implemented. Surveyed coverage (%) refers to a population-based representative sample of households in the MDA areas after the campaign and is defined by the total number of individuals surveyed having taken a dose x 100 / total number of individuals surveyed on whom data is available.
 

Disability Prevention Outcomes

Year

Outcome Measure

2003

31 doctors and surgeons trained in disability management and surgery techniques
248 new lymphedema patients seen in clinics
519 patients enrolled in support groups in Milot

2004

 

2005

 

  

Measures of Success 

 

 

 

 

 

 

top of page


Support

Partners collaborating with the Haitian Ministry of Public Health to implement
the LF program

External

  • CDC
  • Notre Dame University
  • PAHO/WHO
  • Interchurch Medical Assistance
  • LF Support Center
National

  • Hôpital Saint Croix
  • Haitian Medical Association
  • Hôpital Sacre Cœur

Program support is provided by

  • Bill & Melinda Gates Foundation
  • GlaxoSmithKline
  • CDC
  • Interchurch Medical Assistance
  • World Health Organization
  • Honeywell International
  • Presbyterian Women's Organization

Further funding is required to scale up the program to the 90% of people in at-risk areas that are not currently covered by MDA campaigns.  It would expand the number of patient support groups, provide more training in home-based disability treatment, and increase the in-country capacity for hydrocele surgery.  These funds would be used in addition to the contributions the Haitian government has already made in personnel and resources.

 For more information and to provide support to the Haiti LF program or other LF elimination programs contact:

LF Support Center
750 Commerce Drive, Suite 400
Decatur GA 30030
(1) 404-592-1401
gaelf@emory.edu

 

  1. World Factbook and World Bank databases
  2. Lymphatic Filariasis Elimination in the Americas 2002 report

top of page


LF Elimination in the Americas | LF Support Center Home | Background | Research | About Lymphatic Filariasis
LFSC Publications | Resources | LF Links | LFSC Staff | Contact Us | What's New